News

A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.

A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.

Test-drive this 7-fold model in your own practice.

The therapeutic nature of crying, in all professions…

MindMed has announced the dosing of the first patient in its second Phase 3 study of MM120.

New phase 3 data on CYB003 is coming. Learn more about the phase 3 pivotal program here.

At the beginning of this year, US Surgeon General Vivek H. Murthy, MD, MBA, issued a health advisory warning about the link between alcohol use and the risk of cancer. Learn more about its implications for psychiatry here.

A clinician’s search for flexibility, autonomy, and ethical care leads her to a private practice that redefines work-life balance in medicine.

Did you watch the Super Bowl?

Here are highlights from this week in Psychiatric Times, including trial updates and a new approach to treating a surprising condition.

While health care is no game, we certainly are all a team, striving together toward 1 united goal: improving patient care and outcomes.

The current controversy: whether individuals who have transitioned physically and hormonally from a male gender identity to a female gender identity have an undue and significant advantage in sports.

Check out these bite-sized reviews of books related to mental health.

New Hampshire’s mental health system faces ongoing challenges with emergency department boarding, legal concerns over due process, and resource shortages, prompting reforms to improve patient care and access.

Learn more about the latest research on the impact the endocrine system has on major depressive disorder.

Recent data indicates a decline in compassion.

In mice models, opioid delta-receptor agonists showed promise in helping to relieve abdominal pain and regulate bowel movements. Is targeting the brain the best path forward for IBS treatment?

Is our unlimited access to mass media causing more mental health issues?

Explore the theme of mortality and the fleeting nature of time in a poem inspired by Stoic philosophy and personal reflection.

What does Valentine’s Day, Black History Month, Groundhog Day, the Super Bowl, Snoop Dog, Tom Brady, psychiatry, and Ramadan all have in common?

A recent phase 2b trial of GH001 showed promising results for treatment-resistant depression, demonstrating rapid and sustained effects with a favorable safety profile.

What patients are at risk when taking SSRIs?

Olympians are excellent examples of how we can embody resilience, reflecting on our own growth.

Do you want to be featured in a future Special Report? Check out our February theme!

How are Dr Moffic’s social psychiatric resolutions doing? Let’s check in.

Yale School of Medicine and VA Connecticut Healthcare System researchers compared social determinants of health in relation to the risk of suicide, a major global public health issue and one of the leading causes of death in the United States.

Check out the pipeline updates from January!

Here are highlights from this week in Psychiatric Times, including FDA news and a look back at Psychiatric Times through the years.

Meditation using immersive virtual reality devices can help alleviate symptoms of major depressive disorder and generalized anxiety disorder.